science translational medicine介绍

！~医药科学专业解释：转化医学；转化医学就是希望将生物医学研究的关注点放在如何将实验室的研究发现转化导向为有利病人诊断、治疗方法的提高上。

2：网络释义：a--转化或转换医学（Translational Medicine）是近两三年来国际医学健康领域出现的新概念。

b--转译医学(Translational Medicine)c--转换医学（Translational Medicine），又叫转化医学是本世纪从循证医学发展而形成的一个医学实践和干预性流行病学的理念，它融汇基础科学、社会科学、政治科学于一体...d--阿斯利康中国创新中心(ICC)初期将着重进行癌症领域临床前到临床医学之间转化医学(translational medicine)的研究。

广义上讲，转化医学(转化科学)就是使病人直接受益的对基础科学研究的应用。

Open accessAll articles published by Journal of Translational Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.Authors of articles published in Journal of Translational Medicine are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.Article-processing chargesOpen access publishing is not without costs. Journal of Translational Medicine therefore levies an article-processing charge of £1250/$2005/€1560 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.Indexing servicesFollowing publication in Journal of Translational Medicine, the full-text of each article is deposited immediately and permanently archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also in repositories in e-Depot, the National Library of the Netherlands' digital archive of electronic publications. Journal of Translational Medicine is included in PubMed and all major bibliographic databases. A complete list of indexing web services that include BioMed Central's journals can be found here.Journal of Translational Medicine is tracked by Thomson Reuters (ISI)and has an Impact Factor of 3.47.Publication and peer review processAuthors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Translational Medicine, a personalized section of the site.Portability of peer reviewIn order to support efficient and thorough peer review, we aim to reduce the number of times a manuscript is re-reviewed after rejection from Journal of Translational Medicine, thereby speeding up the publication process and reducing the burden on peer reviewers. Therefore, please note that, if a manuscript is not accepted for publication in Journal of Translational Medicine and the authors choose to submit a revised version to another BioMed Central journal, we will pass the reviews on to the other journal's editors at the authors' request. We will reveal the reviewers' names to the handling editor for editorial purposes unless reviewers let us know when they return their report that they do not wish us to share their report with another BioMed Central journal.ReprintsHigh-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.SupplementsJournal of Translational Medicine will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.Editorial policiesAny manuscript, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Information on duplicate/overlapping publications can be found here. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.Correspondence concerning articles published in Journal of Translational Medicine is encouraged. A 'post a comment' feature is available on all articles published by Journal of Translational Medicine. Comments will be moderated by the editorial office (see our Comment policy for further information) and linked to the full-text version of the article, if suitable.Editorial standardsBioMed Central is a member of the Committee on Publication Ethics (COPE) and endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.Ethical guidelinesSubmission of a manuscript to Journal of Translational Medicine implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available if requested by the editorial staff.Journal of Translational Medicine's publisher, BioMed Central, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the publisher if required, will work with authors to ensure an appropriate outcome is reached.The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.Standards of reportingJournal of Translational Medicine supports initiatives aimed at improving the reporting of biomedical research. We recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies. Checklists are available for a number of study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), observational studies (STROBE), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies (STARD) and qualitative studies (RATS). For authors of systematic reviews, an additional file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.Standardised gene nomenclature should be used throughout. Human gene symbols and names can be found in the HUGO Gene Nomenclature Committee (HGNC) database and any enquiries, or requests for new gene symbols, should be directed via email to hgnc@. Nomenclature committees for other species are listed at /about/faq#otherspecies. For mutation nomenclature please use the guidelines suggested by the Human Genome Variation Society.Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.Journal of Translational Medicine also supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform including the ISRCTN register administered by Current Controlled Trials, part of BioMed Central Group.The trial registration number should be included as the last line of the manuscript abstract. Data and materials releaseSubmission of a manuscript to Journal of Translational Medicine implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.Nucleotide sequencesNucleotide sequences can be deposited with the DNA Data Bank of Japan(DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, or GenBank (National Center for Biotechnology Information).Protein sequencesProtein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).The accession numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets with the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).Mass spectrometryCompeting interestsJournal of Translational Medicine requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.Plagiarism detectionJournal of Translational Medicine's publisher, BioMed Central, is a member of the CrossCheck plagiarism detection initiative. In cases of suspected plagiarism CrossCheck is available to the editors of Journal of Translational Medicine to detect instances of overlapping and similar text in submitted manuscripts. CrossCheck is a multi-publisher initiative allowing screening of published and submitted content for originality.Citing articles in Journal of Translational MedicineArticles in Journal of Translational Medicine should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.Article citations follow this format:Authors: Title. J Transl Med [year], [volume number]:[article number].e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Transl Med 2009, 1:115.refers to article 115 from Volume 1 of the journal.Why publish your article in Journal of Translational Medicine?High visibilityJournal of Translational Medicine's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.Speed of publicationJournal of Translational Medicine offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Translational Medicine, BioMed Central and PubMed Central and will also be included in PubMed.FlexibilityOnline publication in Journal of Translational Medicine gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other papers).Promotion and press coverageArticles published in Journal of Translational Medicine are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Translational Medicine's pages and on the BioMed Central homepage.In addition, articles published in Journal of Translational Medicine may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Translational Medicine. A list of articles recently press-released by journals published by BioMed Central is available here.CopyrightAuthors of articles published in Journal of Translational Medicine retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).For further information about the advantages of publishing in a journal from BioMed Central, please click here..。

临床进展CHINESE COMMUNITY DOCTORS中国社区医师2021年第37卷第2期国际癌症研究机构2018年统计表明，乳腺癌的发病率和死亡率位居第2位。

在女性人群中，乳腺癌不仅诊断率最高，并且致死率也十分惊人[1]。

因此，乳腺癌治疗方案的选择极其重要。

乳腺癌的免疫治疗通过人为调节机体的免疫功能以期减少乳腺癌的复发和转移。

目前，乳腺癌的免疫治疗在防治中的作用仍然有待探究。

本文着眼于乳腺癌免疫治疗的大型临床试验进展和应用，总括乳腺癌的免疫治疗方案，为临床工作提供指导和方向。

免疫生物标志物肿瘤浸润淋巴细胞(TILs)是一种免疫生物标志物。

在乳腺癌，尤其在三阴性和HER2阳性的乳腺癌亚型中，TILs 对乳腺癌转移的抑制和预后的改善较为明显。

NeoALTTO 临床试验证实，TILs 的增加与乳腺癌无进展生存期的延长有关[2]。

此外，在一些试验中，TILs 的增加被认为是预后良好的特异性指标。

然而在一些临床试验中结果却恰恰相反。

N9831临床试验显示，未接受曲妥珠单抗的患者有较多的TILs。

虽然在大多数癌症中，如卵巢癌、胃癌、结直肠癌等，TILs 对肿瘤的转移有抑制作用，但在乳腺癌中，TILs 的作用仍然有待探究。

CD39和CD73是腺苷途径中的关键酶，它们可能是乳腺癌未来极具价值的免疫生物标志物。

脂肪来源的间充质干细胞可能对调节性T 细胞的CD73和CD39受体具有诱导作用[3]。

CD39对实体瘤的发生发展具有重要作用。

目前已有研究表明，CD39的表达可以导致肿瘤浸润性CD8+T 细胞衰竭。

近年来，CD73被认为是乳腺癌发生发展中的关键外周核苷酸酶。

缺氧和促炎细胞因子等因素上调肿瘤微环境中的CD73基因，通过酶和非酶途径触发分子和细胞信号通路，最终将促进乳腺癌的侵袭[4]。

此外，靶向阻断CD73可以增强抗PD-1和抗CTLA-4单克隆抗体的治疗活性，因此可能增强针对免疫检查点抑制剂的治疗策略。

science translational medicine介绍
（原创版）
目录
1.Science Translational Medicine 的概述
2.Science Translational Medicine 的内容与领域
3.Science Translational Medicine 的重要性
4.Science Translational Medicine 的未来展望
正文
Science Translational Medicine（STM）是一本国际性的医学研究杂志，它致力于促进基础研究与临床医学之间的交流与转化。

这本杂志是由美国科学促进会（AAAS）出版的，同时也是《科学》杂志的一个分支。

Science Translational Medicine 的内容涵盖了广泛的医学领域，包括生物医学研究、临床研究、药物研发、公共卫生等。

这本杂志的特色在于，它不仅发表原创研究论文，还鼓励作者提交那些能够直接影响临床实践和公共卫生政策的研究成果。

Science Translational Medicine 的重要性体现在，它为全球的医学研究者和临床医生提供了一个交流的平台，使得基础研究能够更快地转化为临床应用。

这对于提高医疗服务的质量，推动医学科学的发展都具有重要的意义。

对于 Science Translational Medicine 的未来展望，我们相信，随着科技的发展，这本杂志将会在更多的领域发挥重要的作用。

第1页共1页。

science translational medicine的影响因子【最新版】目录1.科学翻译医学的影响因子概述2.影响因子的计算方法3.科学翻译医学的影响因子排名4.科学翻译医学的影响因子与学术地位的关系5.科学翻译医学的影响因子对科研人员的意义正文1.科学翻译医学的影响因子概述“科学翻译医学”（Science Translational Medicine，简称 STM）是一本国际知名的学术期刊，旨在促进生物医学研究领域的知识传播与转化。

影响因子（Impact Factor，简称 IF）是衡量一个学术期刊影响力的重要指标，它反映了某个期刊中文章在一定时间内被引用的平均频次。

对于科学翻译医学这本刊物来说，了解其影响因子有助于我们评估其在学术界的地位和影响力。

2.影响因子的计算方法影响因子的计算方法是以某期刊前两年发表的文章在第三年被引用的总次数与该期刊前两年发表文章的总数之比。

例如，计算某期刊 2019 年的影响因子，需要统计 2017 年和 2018 年发表的文章在 2019 年被引用的次数，然后除以 2017 年和 2018 年的文章总数。

3.科学翻译医学的影响因子排名根据我国最新的学术期刊影响因子排名，科学翻译医学在我国生物医学领域具有较高的影响力，其影响因子排名位居前列。

这表明该期刊发表的文章具有较高的学术价值和实用价值，受到了国内外同行的广泛关注和认可。

4.科学翻译医学的影响因子与学术地位的关系影响因子是衡量学术期刊影响力的一个重要指标，但并非唯一的标准。

学术地位的评价还涉及到其他方面的因素，如学术声誉、编辑质量、作者群体等。

然而，影响因子在很大程度上反映了一个期刊的学术地位。

科学翻译医学较高的影响因子表明其在学术界具有较高的地位和声望。

5.科学翻译医学的影响因子对科研人员的意义科学翻译医学的影响因子对科研人员具有重要的参考价值。

首先，高影响因子表明该期刊发表的文章具有较高的学术价值，科研人员可以从中获取最新的研究动态和科研成果。

science translational medicine介绍
Science Translational Medicine 是一份同行评审的科学期刊，由美国科学家出版，主要刊登将基础研究成果转化为临床应用的科学论文。

该期刊于2009年创刊，每周出版一期。

其宗旨是
推动基础科学研究与临床医学之间的桥梁，加速科学发现在疾病诊断、治疗和预防领域的转化。

Science Translational Medicine 发表的论文涵盖了各个研究领域，包括生物学、生物化学、生理学、药理学、临床医学等。

这些论文通常介绍了新的疗法、技术、药物、诊断工具，以及疾病机制的新认识等。

期刊的编辑团队由经验丰富的科学家和医生组成，以确保发表的文章具有高质量和科学可信度。

Science Translational Medicine 推崇跨学科合作和应用导向研究，并鼓励作者在论文中提供实验数据、临床试验结果和相关的数据分析，以使读者能够更好地理解研究的重要性和潜在的临床应用。

该期刊还注重社会影响和伦理问题，对于涉及人类和动物实验的研究，作者需提供相应的伦理批准和知情同意的文件。

Science Translational Medicine 的文章具有高影响力和引用率，被广泛阅读和引用。

它为研究人员、临床医生和生物制药行业提供了一个宝贵的资源，促进了研究和应用之间的互动和合作。

目录1. 亮点研究揭示纳米技术助力人类疾病研究 (2)2. ACS Nano：美科学家研发出新的抗癌技术 (12)3. Biomaterials：科学家发现纳米金棒抗癌分子表型 (15)4. Science Translational Medicine:纳米涂层能将移植物与骨结合 (17)5. Nature Communications：新技术可引导两种不同胶体自动组装 (19)7. Nano Lett.：借助纳米材料控制雄性动物避孕新法 (22)8. Scientific Reports：DNA纳米材料研究新进展 (24)9. Science：DNA纳米技术新进展 (26)10. Small ：DNA可控自组装贵金属纳米结构研究获进展 (28)11. Nanoscale：MRI造影剂材料研究获进展 (31)12. Nat Nano：科学家研发药物降低醉酒小鼠血液酒精浓度 (33)13. ACIE：稀土掺杂无序结构晶体材料光物理研究获进展 (34)14. Nano Lett.:科学家利用电子显微镜首次拍到DNA照片 (36)15. ACS Nano：一种新颖的多任务模式可调式等离子体纳米泡 (38)16. Nanomedicine：利用纳米颗粒开发出新的膀胱癌药物运送系统 (41)17. ACS Nano：自组装纳米丝加强药物运送能力 (42)18. Angew Chem：首次开发出自组装的纳米颗粒进行抗肿瘤的热化疗 (45)19. Nat Methods：利用磁性纳米颗粒同时控制上千个细胞 (46)20. Adv Mater：纳米颗粒形状在基因疗法中发挥着重要作用 (49)21. PNAS：利用硅片计算工具揭示纳米颗粒抑制胰腺癌转移机制 (51)22. ACS Nano：开发出快速检测疾病发生的DNA纳米探针技术 (53)23. Materials Today：一种保护医疗器械生物功效的纳米涂层新技术 (54)24. PNAS：纳米颗粒提高药物疗效 (56)25. Nat Med：利用纳米颗粒开发出治疗深层癌症的光动力疗法 (58)26. PNAS:研究开发出混合纳米纤维生物材料 (60)27. Sci Rep:金纳米粒子对果蝇代谢信号通路的调控作用 (63)28. JACS：一种聚合物纳米膜或可替代蛋白质水化膜 (65)29. Small：日开发出伸缩自如柔软胶囊 (66)30. Plant Cell：林金星等在拟南芥中发现脂筏蛋白介导胞吞的新途径 (68)31. PNAS：邱志刚等发现纳米材料可促进耐药基因在细菌之间转移 (70)32. ENVIRON SCI TECHNOL：纳米粒可能增加植物DNA损伤 (72)33. ACS Nano：纳米注射器递送靶向治疗脑癌的化合物 (75)34. Biomaterials：纳米泡加化疗等于靶向单个癌细胞 (76)35. Sci Transl Med：纳米微粒投药可明显改善化疗效果 (78)36. JACS ：新催化剂——更价廉、更绿色的药物 (81)37. J Am Chem Soc:金纳米粒--开启免疫系统的钥匙 (83)38. Nanoscale：纳米―森林‖可将光和水转化为氢燃料 (85)39. Nano. Lett：纳米技术或可控制蛋白性质 (87)40. Nano Lett.：德发明新方法无需标记即可检测蛋白分子 (88)（最新至2013.10）纳米技术与生物学交叉领域研究进展（中文简报）1. 亮点研究揭示纳米技术助力人类疾病研究2013-9-30 0:15:20关键词：纳米颗粒HIV 癌症药物运输电子皮肤纳米技术（Nanotechnology）也称毫微技术，是研究结构尺寸在1纳米至100纳米范围内材料的性质和应用的一种技术。

医学核心期刊目录2020引言医学核心期刊是指在医学领域具有重要影响力和学术价值的期刊，被广泛认可和引用。

医学核心期刊向医学专业人士提供了最新的科研成果和学术论文，对医学研究和临床实践具有重要意义。

本文将介绍2020年医学核心期刊目录，并对其中一些具有代表性的期刊进行简要介绍。

2020年医学核心期刊目录以下是2020年医学核心期刊目录的一些代表性期刊：1.New England Journal of Medicine（NEJM）2.The Lancet3.JAMA - Journal of the American Medical Association4.British Medical Journal（BMJ）5.Nature Medicine6.Cell7.Science Translational Medicine8.PLoS Medicine9.Clinical Cancer Research10.Circulation11.Diabetes Care12.Neurology13.Journal of Clinical Oncology14.Annals of Internal Medicine15.American Journal of Respiratory and Critical Care Medicine代表性期刊简介1. New England Journal of Medicine（NEJM）New England Journal of Medicine（NEJM）成立于1812年，是医学领域最古老和最具影响力的期刊之一。

NEJM发表了许多临床研究、基础医学研究和公共卫生研究的重要成果。

它涵盖了各个医学领域，包括内科、外科、儿科、神经科学等。

NEJM的审稿严格，质量高，被广泛认可和引用。

2. The LancetThe Lancet成立于1823年，是一本国际性医学期刊，涵盖了各个医学领域。

science translational medicine梅斯影响因子Science Translational Medicine 是一本以科学研究和医学应用为主题的期刊，被广泛认可为全球领先的医学研究杂志之一。

该期刊的影响因子是衡量其刊载的研究文章被引用频率的指标，也是评估期刊学术质量和影响力的重要参考指标。

梅斯影响因子 (MeSH Impact Factor) 是指从医学科学及其临床研究的角度，通过应用MeSH（Medical Subject Headings）词汇进行分类和索引的文章在 Science Translational Medicine 上的被引频次。

MeSH 是由美国国家医学图书馆 (National Library of Medicine, NLM) 维护和开发的术语系统，广泛应用于医学文献分类、检索和索引工作。

Science Translational Medicine 的梅斯影响因子的计算方式与其他学术期刊的影响因子计算方式略有不同。

它通过对刊载的文章进行MeSH词汇分类和标引，统计每篇文章的被引频次，并按照MeSH词汇的不同分类领域进行加权计算，得出期刊的梅斯影响因子。

这种计算方式更加准确地反映了期刊在特定医学领域的影响力和知名度。

梅斯影响因子是期刊的重要评价指标，具体数值的高低反映了该期刊在医学领域的影响力和学术质量。

而Science Translational Medicine 作为科学研究与医学应用的跨学科期刊，在获得高影响因子的同时，也证明了其在医学科学领域的杰出贡献和广泛认可。

随着科学技术的不断进步和医学领域的不断发展，Science Translational Medicine 的梅斯影响因子也在不断变化。

期刊的主编和编辑团队将继续努力，选择高质量的研究文章，推动科学研究与医学应用的交流与合作，确保该期刊在医学领域的影响力和学术质量持续提高。

总结来说，Science Translational Medicine 的梅斯影响因子是评估该期刊在医学科学和应用研究领域影响力的重要指标。

science translational medicine介绍摘要：1.科学转化医学的定义2.科学转化医学的起源和发展3.科学转化医学的重要性4.科学转化医学的应用领域5.科学转化医学在我国的发展现状与挑战6.科学转化医学的未来发展趋势和前景正文：科学转化医学，通常简称为转化医学，是一门结合基础科学研究、临床观察和病患护理的跨学科领域。

转化医学的最终目标是通过加强基础研究和临床研究之间的联系，促进新的医学发现和治疗方法的应用，以提高病患的治愈率和生活质量。

科学转化医学起源于20 世纪90 年代，随着基因测序技术的进步和生物信息学的发展，科学家们开始探索如何将研究成果应用于临床实践。

随着研究的深入，转化医学逐渐成为医学研究的重要方向。

科学转化医学的重要性在于，它将实验室的研究成果与实际的临床治疗紧密结合，从而形成一个良性的循环。

基础研究为临床治疗提供理论依据，而临床观察则可以指导基础研究的方向，为病患提供更有效的治疗方案。

科学转化医学的应用领域广泛，包括疾病机理研究、药物研发、基因治疗、个体化医疗等。

这些应用领域都在很大程度上推动了医学的进步和发展。

在我国，科学转化医学的研究和应用也取得了显著的进展。

政府加大了对医学研究的投入，许多高校和研究机构都设立了转化医学研究中心。

然而，与发达国家相比，我国在转化医学领域的研究水平和应用能力仍有较大的差距，面临着许多挑战，如研究资源分配不均、转化研究的人才短缺等。

展望未来，科学转化医学的发展趋势将更加注重个体化医疗和精准医疗。

随着基因编辑技术的成熟和大数据的普及，科学转化医学将为每个病患提供更为精准和有效的治疗方案。